Because individuals that carry the APOE e4 gene variant surface to have a higher possibility of serious difficulties, the FDA recommends remaining tested for your gene variant before beginning treatment with lecanemab or donanemab. But there is no single consequence. Signs or symptoms may possibly stay secure For several years https://jasonq653scm3.angelinsblog.com/profile